SEARCH RESULTS FOR:
Gil Roth
PRESIDENT, PBOA
"The Ukraine crisis highlighted how Europe needs to look at its energy supply and how it will make sure they have secure supply chains. Part of that has involved the US more closely. Geopolitics will have a more significant impact going forward."
Terry Myerson
CEO, TRUVETA
"Truveta Studio is the first data and analytics solution to study patient care and outcomes for all conditions, drugs, and medical devices. Pfizer is using Truveta Studio to study COVID-19."
Juice Lambert
PRESIDENT, TITAN ENVIRONMENTAL CONTAINMENT
"We must work toward both human safety and environmental safety, and because our products typically prevent issues such as seepage and contamination of the soil and groundwater, mistakes can be very dangerous."
Nigel Fung & Neal Reynolds
PARTNER AMERICAS (NF) & PARTNER (NR), CSA GLOBAL
"Advanced data analysis is a huge growth area, and we are overloaded with opportunities for our team to address issues to optimize operations at the study and operational stages."
James Longshore
CO-FOUNDER AND CEO, XTRA-GOLD RESOURCES
"I strongly believe Kibi has room to grow into a multi-million oz deposit and become the next big discovery in Ghana."
Oliver Dallaway
DIRECTOR, AFRICAN MINING SERVICES (AMS)
"The whole point of our work in the country is to empower Congolese people and give them a sense of achievement. AMS only hires locally."
Ajay Tandon
MANAGING DIRECTOR, VEEDA CLINICAL RESEARCH
"We now offer end-to-end modular technical services, encompassing both pre-clinical and clinical development of biosimilars addressing global regulatory requirements."
Gaurav Kaushik
MANAGING DIRECTOR AND CEO, METEORIC BIOPHARMACEUTICALS
"We are looking into new ways to reap the benefits of artificial intelligence, particularly on the clinical side. On the physical side, Meteoric Biopharmaceuticals will have a new factory and lab up and running by the end of 2024, that will work on advanced fermentation processes."
Liping Liu
FOUNDER & CEO, HIGHTIDE THERAPEUTICS
"As more robust drug candidates are emerging, I am willing to bet that we will have the first NASH drug approved in 2023."
Mining in Ontario and Toronto's Global Reach 2023
GBR’s annual Mining in Ontario and Toronto’s Global Reach 2023 report delves into the themes impacting the global mining sector, comprising analysis based on over 120 interviews with the leading executives from major producers, associations, juniors, consultants, investors and service providers, to provide an in-depth and holistic view of what is happening now, and more pertinently, what could be happening in the months and years ahead.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Latam North and Caribbean Mining 2025 - Digital Interactive
A convergence of high-commodity prices and low valuations, on the back of a structural deficit in exploration and discoveries, has set the perfect scene for increased M&A. The leverage is particularly high for acquisitions in Latam North and the Caribbean, where stocks do not command the high premiums of tier-one jurisdictions. But M&A is only a quick fix to the global resource replenishment crisis.
A convergence of high-commodity prices and low valuations, on the back of a structural deficit in exploration and discoveries, has set the perfect scene for increased M&A. The leverage is particularly high for acquisitions in Latam North and the Caribbean, where stocks do not command the high premiums of tier-one jurisdictions. But M&A is only a quick fix to the global resource replenishment crisis.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
